• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Neulasta (pegfigrastim) injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – June 2011

 

Summary View

ADVERSE REACTIONS

Postmarketing Experience
  • Hypersensitivity Reactions: cutaneous vasculitis to skin and subcutaneous tissue disorders